Eckert & Ziegler stock gains 2.25 percent as H1 profit rises

Published on 10/07/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock gains 2.25 percent on October 7, 2026, while first-half revenue reached EUR 149.3 million. Adjusted EBIT fell 6 percent and three analysts set a Strong Buy consensus.

Pop-Art-Comicbild eines Wissenschaftlers mit leuchtend grünem Radioisotop im Nuklearmedizin-Labor — Eckert & Ziegler DE0005659700 Medizintechnik: Pop-Art-Comic mit Wissenschaftler im Nuklearmedizin-Labor und leuchtender Radioisotopen-Ampulle, Illustration mit AI erstellt.

Eckert & Ziegler stock was trading at EUR 12.29 on Xetra on October 7, 2026, up 2.25 percent, while the share remained 30.7 percent below its 52-week high of EUR 17.73. The market move puts the radiopharmaceutical supplier's half-year performance back at the center of the investment case.

Half-year profit rises as EBIT falls

According to Börse Global on September 11, 2026, Eckert & Ziegler generated EUR 149.3 million in revenue in the first half of 2026, an increase of 0.4 percent from the prior-year period. Adjusted EBIT fell 6 percent to EUR 33.3 million, while consolidated profit rose 4.5 percent to EUR 22.4 million.

The figures show a split performance rather than a broad-based earnings acceleration. Revenue edged higher, but the operating result weakened as delivery delays affected gallium generators and the Isotope Products segment lagged expectations, according to Börse Global.

Guidance demands a stronger second half

The company confirmed its 2026 targets in the period discussed by Börse Global: revenue of EUR 320 million and adjusted EBIT of EUR 80 million. Against first-half revenue of EUR 149.3 million, the target requires EUR 170.7 million in the second half, making execution in Medical and a recovery in Isotope Products central to the outlook.

Eckert & Ziegler's investor page describes two operating segments, Medical and Isotope Products, serving cancer therapy, industrial radiometry, and nuclear medicine diagnostics and therapy. The company reported EUR 312.0 million in fiscal-year 2025 revenue and EUR 77.7 million in adjusted EBIT on its investor-relations page.

Analysts see upside from current level

Investing.com lists a Strong Buy consensus from 3 analysts and an average 12-month price target of EUR 21.60. The target lies 75.8 percent above the EUR 12.29 Xetra price, a comparison that leaves the market's execution concerns visible even alongside the positive rating balance.

The next reported checkpoint is scheduled for November 12, 2026, when Eckert & Ziegler is listed to publish third-quarter results by MarketScreener. That date should clarify whether the company is converting its confirmed annual targets into operating progress.

Stock stays near its yearly low

Eckert & Ziegler stock was last at EUR 12.29 on Xetra at 1:32 p.m. CEST on October 7, 2026, with a market capitalization of EUR 769.1 million and volume of 75,702 shares. Its 52-week range was EUR 11.91 to EUR 17.73, leaving the share EUR 0.38 above the low.